Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07519395 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)

Study acronym: BALANCE
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 110 → 114 locations
    • Eligibility criteria expanded, about 68 words
    • Secondary endpoints revised (16)
  2. Recruitment openedv2 Show 4 more changesShow less
    • Trial sites expanded: 0 → 110 locations
    • Primary completion date: Mar 5, 2027 to Mar 9, 2027
    • Study completion date: Jul 9, 2027 to Jul 13, 2027
    • Start date changed from estimate of Apr 6, 2026 to Apr 8, 2026
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
GlaxoSmithKline
246 trials monitored
See 20 trials at risk
This study is designed to evaluate the efficacy and safety of camlipixant in adults with IBS-D and IBS-M. The study has two parts. After the first part, some participants will be randomly chosen again to either get a higher dose or stop the drug.
Trial Details
NCT Number NCT07519395
Lead Sponsor GlaxoSmithKline
Conditions
(from sponsor)		 Irritable Bowel Syndrome
Related terms Irritable Bowel Syndrome
Enrollment 420 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov